## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.98 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($1051.63)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 2)

**1. Indiana sues Eli Lilly alleging insulin price-fixing scheme**
- Source: WFYI | 20260105T200831 | Bearish | Relevance: 100%
- Indiana has filed a lawsuit against Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical company of inflating insulin prices through a secret rebate scheme with pharmacy benefit managers. The state alleges Lilly conspired to artificially raise sticker prices for insulin, driving up costs for patients despite low manufacturing costs. Eli Lilly asserts it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket expenses and cutting list prices.

**2. Indiana sues Eli Lilly over insulin prices**
- Source: WTHR | 20260105T110100 | Somewhat-Bearish | Relevance: 100%
- The state of Indiana is suing pharmaceutical giant Eli Lilly and Company, accusing it of colluding with other insulin makers to inflate insulin prices by over 1,000% in the last decade. Attorney General Todd Rokita is seeking market changes, damages, and penalties. Eli Lilly denies the allegations, stating it has made insulin more affordable and committed significant investment in the U.S.

**3. Ventyx Biosciences said to be in takeover talks with Eli Lilly, shares surge**
- Source: Sharecast.com | 20260107T130944 | Bullish | Relevance: 100%
- Ventyx Biosciences shares surged after reports that Eli Lilly & Co. is in advanced talks to acquire the company for over $1 billion. Ventyx specializes in developing treatments for inflammatory diseases like Crohn's and rheumatoid arthritis, and its drug candidates also show promise for neurodegenerative and heart-related conditions. The potential acquisition would significantly expand Eli Lilly's immunology portfolio.

**4. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal**
- Source: The Boston Globe | 20260106T120921 | Bullish | Relevance: 100%
- Boston-based Nimbus Therapeutics has announced a partnership with Eli Lilly & Co. to develop a new oral obesity treatment in a deal potentially worth up to $1.3 billion. This collaboration highlights the ongoing race to develop more accessible and affordable weight-loss medications, particularly oral forms, given the high costs and insurance challenges associated with existing injectable treatments. The agreement involves Nimbus receiving $55 million upfront and potential milestone payments and royalties.

**5. Lillyâ€™s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones**
- Source: BioSpace | 20260105T160930 | Bullish | Relevance: 100%
- Eli Lilly is projected to achieve $94.3 billion in annual revenue by 2027, with 2026 being a pivotal year driven by growth in the oral obesity drug market. Key milestones include the anticipated approval of Lilly's oral obesity drug orforglipron and the readout of crucial Phase III trials, as the company fiercely competes with Novo Nordisk. Analysts expect Lilly to maintain an edge in the oral obesity market due to its easier-to-manufacture small molecule drug candidates.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 23 ($203.82M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $204M sold (23 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 33.9x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Insider selling cluster ($203.8M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $993.4B |
| Beta | 0.35 |
| 52W Range | $623.78 - $1117.66 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 33.9 |
| Current P/E | 46.8 |
| YoY Growth | 38.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 3.9% (minimal 5-day change). Below STRENGTH zone by 0.1pp (needs >4.0% for momentum thesis). MRS_5 at 2.4% confirms short-term momentum alignment. AM_20 at 4.8% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.73), momentum weakening. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.86% (CS: 81) | Neutral |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | -1.73 | Bearish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.094x | Above |
| vs SMA200 | 1.332x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1107.71
- **Stop Loss:** $1051.63 (5.1% risk)
- **Target:** $1219.87 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 21
- **Position Value:** $23,261.91
- **Portfolio %:** 23.26%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*